Loading...
Market
Bayer's hormonal IUD market share change by June 2025?
2
Resolution / Starting Odds
Increase by 1% or more • 25%
No significant change • 25%
Decrease by up to 1% • 25%
Decrease by more than 1% • 25%
Market analysis reports from reputable firms like Statista or MarketWatch
Story
JAMA Study Links Bayer and AbbVie's Hormonal IUDs to Increased Breast Cancer Risk
Oct 16, 2024, 04:00 PM
A recent cohort study published in JAMA on Monday has found an association between the use of levonorgestrel-releasing intrauterine systems (IUDs) and an increased risk of breast cancer in females aged 15 to 49 years. The study indicates that while the risk remains low overall, it is higher compared to nonuse. Bayer, a dominant player in the hormonal IUD market with products such as Kyleena, Mirena, and Skyla, could be significantly impacted by these findings. AbbVie, which produces the IUD Liletta, is also mentioned in the context of this research. This study raises concerns about the safety of hormonal birth control devices used by millions of women worldwide.
View original story
Similar markets
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Decrease by more than 10% • 25%
No significant change (within 10%) • 25%
Increase by 10-20% • 25%
Increase by more than 20% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
Outside Top 10 • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-5% • 25%
6-10% • 25%
11-15% • 25%
Over 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%